BioSpace News Archive

Genetown

BiomX Announces Second Closing of $7.5 Million Private Placement

BiomX Inc. announced the second closing of its recently announced $7.5 million private placement investment.

May 5, 2023
·
4 min read
Business

Rapid Micro Biosystems Reports First Quarter 2023 Financial Results

Rapid Micro Biosystems, Inc. today announced its financial results for the first quarter ended March 31, 2023.

May 5, 2023
·
9 min read
Business

Oncolytics Biotech® Reports First Quarter 2023 Financial Results and Operational Highlights

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2023.

May 5, 2023
·
14 min read
Drug Development

Seres Therapeutics to Host First Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2023

Seres Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on May 9, 2023 at 8:30 a.m. ET to discuss first quarter results and provide a general business update, including initial SER-155 Phase 1b safety and pharmacology results from study Cohort 1.

May 5, 2023
·
1 min read
FDA

Dr. Reddy’s Laboratories Announces the Launch of Regadenoson Injection 0.4 mg/5 mL in the U.S.

Dr. Reddy’s Laboratories Ltd. today announced the launch of Regadenoson Injection in the U.S. market, a generic therapeutic equivalent of Lexiscan® (Regadenoson) injection, approved by U. S. Food and Drug Administration (USFDA).

May 5, 2023
·
3 min read
Deals

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023

Curis, Inc. today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Development Officer, Jonathan B. Zung , Ph.D. to purchase a total of 500,000 shares of Curis common stock, with a grant date of May 1, 2023 (the “Inducement Grant”).

May 5, 2023
·
2 min read
Business

Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023

Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, will release its financial results for the first quarter ended March 31, 2023, on Friday, May 12, 2023.

May 5, 2023
·
2 min read
Business

Twist Bioscience Reports Fiscal Second Quarter 2023 Financial Results

Twist Bioscience Corporation today reported financial results and business highlights for the second quarter of fiscal 2023 ended March 31, 2023.

May 5, 2023
·
16 min read
Genetown

New Assessment Scale to Capture Patient Relevant Bleeding to be Presented at ISPOR 2023

Anthos Therapeutics announced the Company will present four posters at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.

May 5, 2023
·
7 min read
Business

Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time

Assertio Holdings, Inc., a specialty pharmaceutical company offering differentiated products to patients, announced that it will release first quarter 2023 financial results on Tuesday, May 9, 2023, before the market open.

May 5, 2023
·
1 min read